Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07674680 · ClinicalTrials.gov registry record · Early Phase 1
Beta3-adrenergic Receptors and Cardiovascular Function in Aging Women
A Early Phase 1 study, sponsored by University of Missouri-Columbia.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
NCT07674680 is a Early Phase 1 study that has not yet begun recruiting, run by University of Missouri-Columbia. The registered enrollment target is 60 participants.
The verdict
NCT07674680, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Missouri-Columbia.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
We hypothesize vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.
Interventions
- DRUG Placebo
- DRUG Gemtesa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-07 |
| Est. Completion | 2029-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07674680
The ClinicalTrials.gov registry entry for NCT07674680 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07674680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07674680 about?
NCT07674680 is a clinical study titled "Beta3-adrenergic Receptors and Cardiovascular Function in Aging Women". We hypothesize vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.
What is the current status of trial NCT07674680?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2026-07. Estimated completion is 2029-05.
What interventions are being tested in trial NCT07674680?
The interventions under investigation include: Placebo (DRUG), Gemtesa (DRUG).
Who is sponsoring clinical trial NCT07674680?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.